December 10, 2025

Is WHO Mpox Monitoring Window Too Short?

New data challenge WHO's 21-day observation window, as nearly one-quarter of infections develop rash after recommended surveillance period ends.

Conexiant

December 05, 2025

On the Edge of a Measles Comeback?

New analysis examines rising U.S. measles outbreaks, associated clinical risks, and the potential loss of measles-elimination status.

KFF Health News

December 05, 2025

Fancy Gadgets, Higher Bills: HSA Era

Republican proposals to expand health savings accounts amid expiring ACA subsidies outline potential shifts in coverage costs and limitations in how patients may use HSA funds.

KFF Health News

November 17, 2025

‘Patent Dance’ Delays Biosimilars Despite FDA Shift

The FDA moves to speed biosimilar approvals, but rising patent barriers may still delay lower-cost alternatives.

Conexiant

October 29, 2025

FDA Pushes Faster, Cheaper Route for Biosimilar Approval

The FDA released new draft guidance to streamline biosimilar development.

Conexiant

October 20, 2025

Which Hair Loss Treatments Truly Deliver Results?

Researchers compare prescription and over-the-counter treatments for male hair loss to determine which best improve hair density.

Conexiant

October 01, 2025

Remibrutinib Gains FDA Nod for Urticaria

First oral BTK inhibitor approved for antihistamine-resistant chronic spontaneous urticaria, targeting mast cell–driven immune dysregulation

Conexiant

September 29, 2025

FDA Expands Options for Pediatric Psoriasis, PsA

The FDA has approved the first IL-23 inhibitor for pediatric patients with plaque psoriasis and psoriatic arthritis.

Conexiant

September 19, 2025

New Topical JAK Inhibitor Option for Kids

The FDA approved ruxolitinib cream for children aged 2 to 11 with mild to moderate atopic dermatitis.

Conexiant